Alnylam Pharmaceuticals has capped off a busy month of breakthrough therapy recipients, with the company announcing the designation May 31 for its ALN-AS1 (givosiran) an RNAi treatment designed for the prevention of attacks in patients with acute hepatic porphyria.
A family of rare diseases, acute hepatic porphyrias can result in patients experiencing severe neurovisceral attacks that can lead to...






